HIV-associated lipodystrophy and excess visceral adiposity — compounds assessed
The 1 compound the Institute assesses in hiv-associated lipodystrophy and excess visceral adiposity.
§4Compounds assessed
Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.
-
Visceral adipose tissue reduced by 15.2 % versus 5.0 % increase with placebo at 26 weeks — Two pivotal trials in HIV-associated lipodystrophy with computed-tomography endpoints. Downgraded for indirectness when applied to any population outside that…
Moderate
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine 2007;357(23):2359–2370. doi:10.1056/NEJMoa072375 · PMID 18052660
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.